Header
For Healthcare Professionals

India: EMPAGLIFLOZIN + LINAGLIPTIN = A POWERFUL COMBINATION

EMPAGLIFLOZIN + LINAGLIPTIN = A POWERFUL COMBINATION Banner

Demonstrates robust safety of the 2 organ*systems2-5

why glyxambi heart image
38% RRR in CV death | 35% RRR in in HHF with empagliflozin2 NO INCREASED RISK OF HHF with linagliptin10
why glyxambi kidney image
39% RRR in incident or worsening nephropathy with empagliflozin5 | 14% RRR in albuminuria progression with with linagliptin3

2 proven T2DM medications working together to provide robust CV-HF-Renal outcomes2-5

*Heart and kidney

Glyxambi works in 3 pathways banner

Demonstrates lower risk of 2 adverse events6-9

Lower incidence of hypoglycaemic events with empagliflozin
9x | 5x 
Lower incidence of hypoglycaemic events with empagliflozin & linagliptin respectively vs glimepiride6,8
Potential lower
49% RRR in genital tract infections vs. SGLT2i alone9 (meta-analysis)

2 proven T2DM medications working together to reduce 2 most common adverse events6-9

*Heart and kidney

Glyxambi works in 3 pathways banner

RETHINK THE MATH to manage T2DM

References

  1. GLYXAMBI® India pack insert version. 15 May 2024.

  2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128.

  3. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79.

  4. Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155-1166.

  5. Wanner Ch, Inzucchi SE, Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(18):1801-1802.

  6. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38(3):384-393. 

  7. Hattori S. Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance. Diabetol Metab Syndr. 2018;10:93. 

  8. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38(3):394-402. 

  9. Fadini GP, Bonora BM, Mayur S, et al. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2018;20(3):740-744. 

  10. Thrasher J. Am J Med. 2017 Jun;130(6S):S4-S17. doi: 10.1016/j.amjmed.2017.04.004. PMID: 28526182.